Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2006 Jan 25.

Published in final edited form as: Oncogene. 2005 Jul 21;24(31):4993–4999. doi: 10.1038/sj.onc.1208683

Fig. 2 — Western blot analysis and NFκB function assay. (A) DLD1, 293 and normal human bronchial epithelial cells (HBE) treated with 10 or 50 nM bortezomib for 24 h. (B) DLD1 cells treated with 100 nM paclitaxel or 50 nM bortezomib for various times as indicated. (C) DLD1 cells treated with 0.1 to 5 μM bortezomib for 6 hours as described in Figure 1A. (D) NFκB function detected by EMSA. DLD1 cells treated with 100 nM bortezomib for 0 to 24h or with 10 to 500 nM bortezomib for 24h. DLD1 cells treated with PBS or 20 nM TNFα were used as mock (−) or positive (+) controls. Data represent one of two independent experiments with similar results.

Fig. 2 — Western blot analysis and NFκB function assay. (A) DLD1, 293 and normal human bronchial epithelial cells (HBE) treated with 10 or 50 nM bortezomib for 24 h. (B) DLD1 cells treated with 100 nM paclitaxel or 50 nM bortezomib for various times as indicated. (C) DLD1 cells treated with 0.1 to 5 μM bortezomib for 6 hours as described in Figure 1A. (D) NFκB function detected by EMSA. DLD1 cells treated with 100 nM bortezomib for 0 to 24h or with 10 to 500 nM bortezomib for 24h. DLD1 cells treated with PBS or 20 nM TNFα were used as mock (−) or positive (+) controls. Data represent one of two independent experiments with similar results.